Biotech | November 30, 2021
Thermo Fisher Scientific’s new CRISPR Genome editing protein
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
This strategic collaboration will enable continued innovation in cancer care
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Since its inception, the company has either acquired or taken a majority stake in five companies
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
